Investigation of Microbiome-Derived Metabolite Production in Response to a Mediterranean Diet

Food Habits Clinical Trial

— META  

Official title:

Investigation of Microbiome-Derived Metabolite Production in Response to a Mediterranean Diet

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03783260
• Other study ID #: 2018-262
• Status: Completed
• Phase: N/A
• Start date: January 7, 2019
• Est. completion date: December 1, 2019

Study information

• Verified date: February 2020
• Source: Laval University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project proposes to characterise the microbiome-derived metabolites produced upon ingestion of bioactive precursor-rich meals by healthy volunteers in order to investigate the relationship between gut microbiome composition and the nature of dietary metabolites production.

Description:

There is a large inter-individual variability in gut microbiome-derived metabolites production upon ingestion of similar meals. Since many of these microbiome-derived metabolites have enteric and systemic biological effects, these variabilities could in part account for the different responses to meals and diets.

This project thus aims to improve the understanding the relationship between gut microbiome composition and the nature of dietary metabolites produced from similar bioactive precursor-rich meals.

The investigators therefore propose to characterise the circulating microbiome-derived metabolite profiles in healthy individuals fed the same 2-day precursor-rich Mediterranean diet prior to and after a 2-week of habitual Canadian diet feeding.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 1, 2019
• Est. primary completion date: April 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Men and women aged between 18 and 35 years

• Body mass index between 18.5 and 30 kg/m2

• General good health

• Computer and Internet access

• Basic understanding of written French

Exclusion Criteria:

• Intestinal pathologies including inflammatory bowel disease and gastrointestinal cancers

• Pregnant and/or breast-feeding women

• Alcohol consumption greater than 15 portions for men and 10 for women weekly

• Active tobacco usage

• Consumption of dietary supplements (e.g. multivitamins, omega-3, probiotics)

• Completion of a course of antibiotics in the past 3 months

• Regular use of anti-inflammatory drugs, or use in the past 3 months

• Important weight change (+/- 5 kg) in the past 6 months

• Allergies or food intolerances to ingredients present in trial diets

Related Conditions & MeSH terms

• Food Habits

Intervention

Other:
• Mediterranean diet
During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.

Locations

Country	Name	City	State
Canada	Institut sur la nutrition et les aliments fonctionnels - INAF	Québec	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Laval University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microbiome-derived metabolite profiling	Plasma and urine metabolomics profiling of gut-microbiome derived metabolites (e.g., branched-chain amino acids [BCAA], short chain fatty acids [SCFA], trimethylamine [TMA], amino acids- and polyphenol-metabolites) will also performed at the same time points.	19 days
Primary	Gut microbiome characterisation	Fecal microbiome composition will be characterise by rRNA 16S sequencing prior to and following both 2-day Mediterranean diet periods. Relevant indexes of microbiome diversity (e.g. Shannon beta-diversity), ratios between meaningful bacterial markers of gut dysbiosis (e.g. Firmicutes:Bacteroidetes) and specific microbiome differences in bacterial Families, Genera or species between study periods and individuals.	19 days
Secondary	Endocannabinoid interaction with interindividual microbiome composition	Interindividual variations in the endocannabinoid levels following a 2-day Mediterranean diet intervention according to individual gut microbiome composition will also be characterised. N-acyl ethanolamines, acylglycerols and omega-3 derived endocannabinoids will be quantified by LC MS-MS in plasma and urine samples collected prior to and following both 2-day Mediterranean diet periods.	19 days